Conformational Restriction via Cyclization in β-Amyloid Peptide Aβ(1-28) Leads to an Inhibitor of Aβ(1-28) Amyloidogenesis and Cytotoxicity  by Kapurniotu, Aphrodite et al.
Chemistry & Biology, Vol. 10, 149–159, February, 2003, 2003 Elsevier Science Ltd. All rights reserved. DOI 10.1016/S1074-5521(03)00022-X
Conformational Restriction via Cyclization in
-Amyloid Peptide A(1-28) Leads to an Inhibitor
of A(1-28) Amyloidogenesis and Cytotoxicity
[14, 24] in short amyloid core-containing A sequences
has resulted in inhibitors or modulators of A amyloido-
genesis and cytotoxicity.
In this work, a strategy to “transform” an amyloido-
genic sequence into a nonamyloidogenic one that is
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2 Department of Biochemistry able to interact with the native amyloid-forming se-
quence and inhibit amyloid formation and cytotoxicityand Molecular Cell Biology
Institute of Biochemistry was tested on the N-terminal A sequence A(1-28).
According to the design approach, a sequence part ofUniversity Hospital of the RWTH Aachen
D-52074 Aachen A that may be directly involved in the transition of a
potential -helical state into  sheets and in A-A self-Germany
recognition and self-assembly [17–19, 21, 25–31] was
conformationally constrained into an non- state via
side chain-to-side chain cyclization. We present the de-Summary
sign and study of the biochemical and biophysical prop-
erties of the cyclic analog, its ability to inhibit amyloidThe aggregation process of -amyloid peptide A into
formation and cytotoxicity of A(1-28), and its interfer-amyloid is strongly associated with the pathology of
ence with A(1-40) amyloidogenesis.Alzheimer’s disease (AD). Aggregation may involve a
transition of an  helix in A(1-28) into  sheets and
Resultsinteractions between residues 18–20 of the “A amy-
loid core.” We applied an i, i4 cyclic conformational
Analog Designconstraint to the A amyloid core and devised side
The mechanism of the conformational transition of mo-chain-to-side chain lactam-bridged cyclo17, 21-[Lys17,
nomeric A into amyloid is not yet known. ProposedAsp21]A(1-28). In contrast to A(1-28) and [Lys17, Asp21]
mechanisms include a transition of a potential  helixA(1-28), cyclo17, 21-[Lys17, Asp21]A(1-28) was not able
in the N-terminal sequence A(1-28) into aggregated to form  sheets and cytotoxic amyloid aggregates.
sheets [18, 19, 21, 25], possibly via -helical oligomersCyclo17, 21-[Lys17, Asp21]A(1-28) was able to interact
[32], and amyloidogenesis via a collapsed coil confor-with A(1-28) and to inhibit amyloid formation and cy-
mation [31]. A(1-28) is a conformationally flexible se-totoxicity. Cyclo17, 21-[Lys17, Asp21]A(1-28) also inter-
quence that has been proposed to exist in an -helicalacted with A(1-40) and interfered with its amyloido-
state or as  sheet-containing amyloid aggregates [18,genesis. Cyclo17, 21-[Lys17, Asp21]A(1-28) or similarly
19, 21, 25, 33, 34]. A(1-28) amyloid fibrils are indistin-constrained A sequences may find therapeutic and
guishable from A fibrils [33, 35]. Because the transitiondiagnostic applications in AD.
of A(1-28) into sheets has been proposed to modulate
A amyloidogenesis, this sequence has been often ap-
Introduction plied as a model peptide for A [18–21, 25, 33, 34, 36,
37]. Although it is clear that A(1-28) per se does not
One of the main features of Alzheimer’s disease (AD) correspond to a physiologically relevant sequence for
comprises deposition of extracellular plaques and asso- AD, its use as a model sequence for A should assist
ciated neuronal injury in the brains of AD patients [1]. in understanding the mechanism and the development
The plaques consist of amyloid fibrils of the -amyloid of inhibitors of amyloidogenesis and related cytotox-
peptide (A) which is a 40 (A(1-40)) to 42 (A(1-42)) icity.
amino acid long peptide [1, 2]. The soluble monomeric To constrain A(1-28) in a non- conformation, we
form of A is present under both normal and disease applied the i, i4 side chain-to-side chain cyclization
conditions in the cerebrospinal fluid (CSF) and blood approach, and a Lysi, Aspi4 pair was used to generate
[3]. However, aggregation of A into amyloid has been the lactam-bridged analog cyclo17, 21-[Lys17, Asp21]A(1-
strongly associated with the pathological sequelae of 28) (Figure 1, scheme) [38–40]. The Lys17, Asp21 pair was
AD [1, 4]. One reason for this is that A oligo- and chosen because such a bridge has previously been
multimeric aggegates, contrary to monomeric A, ex- shown to be able to stabilize the -helical conformation
hibit cytotoxic and neurotoxic effects [5–10]. in conformationally flexible polypeptides [40–44]. As to
Several A aggregation and amyloid formation inhibi- the complexity of the synthesis of the compound, it may
tory approaches have been investigated over the past have been simpler to constrain peptide conformation
10 years [11–17]. A amyloidogenesis has been sug- through a Cys, Cys bridge [45]. As the bridge was to be
gested to proceed via a conformational transition of introduced into A, which is a highly aggregation-prone
monomeric A into  sheet aggregates [18–22]. Inhibi- sequence, we chose to use a lactam bridge instead of
tion of  sheet formation via introduction of  sheet- a disulfide bridge due to the various conformational and
“breaking” residues [12, 13, 16, 17, 23] or sequences chemical factors that may determine formation and sta-
bility of a disulfide bridge and the susceptibility of free
thiol-containing sequences to aggregation [46, 47].*Correspondence: akapurniotu@ukaachen.de
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Figure 1. Scheme Showing Primary Structure
of A(1-28), Cyclo17, 21-[Lys17, Asp21]A(1-28),
and [Lys17, Asp21]A(1-28)
Residues of the “A-A self-recognition” se-
quence 18–20 are in bold. Charged residues
are written in italics. Residues Leu17 and Ala21
that were substituted by Lys and Asp, respec-
tively, are underlined. The one-letter code is
used for the amino acids with the exception
for residues 17 and 21. The lactam bridge in
cyclo17, 21-[Lys17, Asp21]A(1-28) and the func-
tional groups of the side chains of Lys17 and
Asp21 in [Lys17, Asp21]A(1-28) are also shown.
The lactam-bridged residues were placed at positions of A(1-28) (Figure 2A) exhibited a sharp absorbance
maximum at 1627 cm1 (Figure 2C) that is usually as-17 and 21 because it has been proposed that the A
signed to  sheet [33, 35, 54]. By contrast, the spectrumamyloid formation process might be associated with an
of cyclo17, 21-[Lys17, Asp21]A(1-28) had a broad ab-unfolding of a helix between residues 13 and 20 [21, 25,
sorbance maximum at 1650–1670 cm1 and indicated34]. We hypothesized that stabilization of this part of
that non- conformations were predominant [54].the helix might inhibit amyloidogenesis. A second rea-
son was that it has been suggested that interactions of
CD and EM Studies on the  Sheet-Formingthe side chains of the hydrophobic residues Val18, Phe19,
Potential and Amyloidogenicity of Cyclo17, 21-and Phe20 might directly contribute to A self-associa-
[Lys17, Asp21]A(1-28), A(1-28)tion with sequence (18–20) serving as an “A-A self-
The transition of soluble A(1-28) into amyloid was fol-recognition” sequence [17, 21, 23, 26, 28–31]. Therefore,
lowed by circular dichroism (CD) spectroscopy and elec-the amino acid constitution of sequence (18–20) should
tron microscopy (EM) under amyloidogenesis-promot-be kept intact to enable for the interaction with A to
ing conditions. As shown in Figure 3A, A(1-28) wasoccur and should become conformationally constrained,
in a mainly disordered state mixed with some orderedwhich would render the analog unable to form extended
elements at the beginning of the aging process [55]. The sheets as in fibrillar aggregates [26]. To differentiate
spectrum did not change over the next 17 hr, and EMthe effects of constraining the conformation via cycliza-
showed a complete absence of fibrillar aggregates (datation from potential effects of the substituents them-
not shown). Then, the shape and position of the mini-selves, [Lys17, Asp21]A(1-28) was also studied.
mum of the spectra changed and a time-dependent red
shift of the minimum from 202 nm (between 0 and 17
AFM, CR Binding, and FT-IR Studies on the  hr) to 208 nm (at a time point of about 21 hr) was ob-
Sheet-Forming and Amyloidogenic Properties of served. The shift was indicative of the formation of sig-
A(1-28) and Cyclo17, 21-[Lys17, Asp21]A(1-28) nificant amounts of more ordered conformeric popula-
The amyloidogenic and  sheet-forming potentials were tions [55]. The conformational transition of A(1-28) was
first studied using highly concentrated (1 mM) solutions completed at 25 hr (Figures 3A and 3B): the spectrum
of the synthetic peptides aged for 2 months at 4C. Such had a strong minimum at 220 nm that suggested that 
aging conditions appear rather extreme. However, these sheet was the predominant conformeric state [49, 55],
conditions or conditions similar to those used here have and insoluble aggregates appeared. EM showed that
often been applied to simulate in vitro conditions of the aggregates consisted predominantly of fibrils
local supersaturation that may lead to in vivo amyloid (Figure 3B).
formation [23, 30, 33, 48–51]. Denaturating electrophore- The ability of cyclo17, 21-[Lys17, Asp21]A(1-28) to aggre-
sis (NuPAGE), reverse phase high-pressure liquid chroma- gate into  sheets and amyloid was studied next. Figure
tography (RP-HPLC), and mass spectroscopic (MALDI- 3C shows the CD spectra of a solution of cyclo17, 21-[Lys17,
MS) analyses of the aged solutions suggested that no Asp21]A(1-28) immediately following the beginning of
peptide degradation had occurred (data not shown). the incubation and 8 days later. No changes were ob-
Atomic force microscopy (AFM) showed that aged served during the 8 day period. The spectrum of
A(1-28) predominantly consisted of long amyloid fibrils cyclo17, 21-[Lys17, Asp21]A(1-28) had minima at 206 nm
(1–8 m) and wound fibrillar bundles with diameters of and in the region of 220–225 nm and was indicative
7–13 nm and an axial periodicity of 28 nm [33, 52] of mixtures of random coil with significant amounts of
(Figure 2A). No amyloid fibrils were detected in aged ordered populations [55]. No amyloid assemblies were
cyclo17, 21-[Lys17, Asp21]A(1-28) (Figure 2D). A(1-28) also detected by EM during the aging process (Figure 3D).
bound congo red (CR) and exhibited green/yellow bire-
fringence under polarized light characteristic for amyloid Studies on the  Sheet and Amyloid-Forming
[53] (Figure 2B). On the contrary, cyclo17, 21-[Lys17, Potential of [Lys17, Asp21]A(1-28)
Asp21]A(1-28) did not exhibit any birefringence (Figure FT-IR, CR staining, and EM showed that [Lys17,
Asp21]A(1-28) had, similarly to A(1-28), both a pro-2E). The Fourier-transformed infra red (FT-IR) spectrum
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Figure 2. Amyloidogenic and  Sheet-Forming Potentials of A(1-28) versus Cyclo17, 21-[Lys17, Asp21]A(1-28) as Assessed by AFM, CR Staining
and Polarization Microscopy, and FT-IR
(A) AFM image (10  10 m; bar 2 m) of aged A(1-28).
(B) Microscopic examination of aged A(1-28) following CR staining under normal field (on the left) and under polarized light (on the right).
(C) FT-IR spectrum of aged A(1-28).
(D) AFM image (7  7 m; bar, 2 m) of aged cyclo17, 21-[Lys17, Asp21]A(1-28).
(E) Microscopic examination of aged cyclo17, 21-[Lys17, Asp21]A(1-28) following CR staining under normal field (on the left) and under polarized
light (on the right).
(F) FT-IR spectum of aged cyclo17, 21-[Lys17, Asp21]A(1-28).
nounced  sheet-forming potential (FT-IR absorbance CD, EM, Size Exclusion Chromatography, and Cell
Viability Studies on the Interaction and themaximum was at 1627 cm1) and strong amyloidogenic
properties (data not shown). CD showed that aging of Inhibitory Effect of Cyclo17, 21-[Lys17, Asp21]A(1-28)
[Lys17, Asp21]A(1-28) resulted in a conformational transi- on  Sheet, Amyloid Formation, and
tion into  sheets and insoluble aggregates (data not Cytotoxicity of A(1-28)
shown). EM showed that the aggregates consisted of Incubations of a mixture of cyclo17, 21-[Lys17, Asp21]A(1-
amyloid fibrils that were indistinguishable from those of 28) with A(1-28) were performed, and the effect of aging
A(1-28) [33, 35, 52]. on conformation and amyloid formation was followed
at various time points in parallel by CD (Figure 5A) and
EM (Figure 5C). The spectrum of the mixture did notCD Studies on the -Helical Propensity
change over 8 days, corresponding to the time rangeof Cyclo17, 21-[Lys17, Asp21]A(1-28)
of the CD study, and the solution remained clear. TheCD spectra of A(1-28) and cyclo17, 21-[Lys17, Asp21]A(1-
spectrum of the mixture strongly differed from that cor-28) were measured under nonamyloidogenic and very
responding to the mathematical sum of the CD spectraweak helix-promoting conditions [18, 19, 21, 35] (Figure
of each of the mixture components alone (Figure 5A).4). The spectrum of A(1-28) exhibited a minimum at 205
This indicated that the two peptides might have inter-nm and indicated the presence of significant amounts of
acted [56]. No amyloid fibrils could be detected by EMrandom coil mixed with other ordered elements [55]
(Figure 5C) not only at the time point of 8 days but also(Figure 4). Of note, this spectrum was very similar to the
up to 3 weeks. By contrast, aggregation of A(1-28)one that has previously been obtained by Barrow et al.
alone into  sheets (Figure 3A) and amyloid (Figure 3B),[19]. The spectrum of [Lys17, Asp21]A(1-28) was very
even at half of the concentration applied in the mixingsimilar to that of A(1-28) (Figure 4). By contrast, the
experiment, was accomplished already at 25 hr of aging,spectrum of cyclo17, 21-[Lys17, Asp21]A(1-28) had a maxi-
while, at the same concentration as that applied in themum at 195 nm and two pronounced minima at 208 and
mixture, A(1-28) aggregated into amyloid between 2222 nm (Figure 4), consistent with the presence of higher
and 6 hr (Figure 5B). In another series of experiments,amounts of -helical structure in the cyclic analog than
in A(1-28) and [Lys17, Asp21]A(1-28) [55]. cyclo17, 21-[Lys17, Asp21]A(1-28) was also found to inter-
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Figure 3. Conformational Transitions in the Process of Amyloid Formation by A(1-28) versus Cyclo17, 21-[Lys17, Asp21]A(1-28) as Assessed by
CD and EM
(A) Far-UV CD spectra of A(1-28) (225 M) at time 0 hr after beginning the incubation and at the indicated time points thereafter.
(B) Electron micrograph of the A(1-28) solution shown under (A) at the time point of 25 hr and 30 min.
(C) Far-UV CD spectra of cyclo17, 21-[Lys17, Asp21]A(1-28) (450 M) at time 0 hr after beginning the incubation and 8 days thereafter.
(D) Electron micrograph of a solution of cyclo17, 21-[Lys17, Asp21]A(1-28) (450 M; see [C]) 8 days following the beginning of incubation. Bars
in the electron micrographs represent 100 nm.
act with and completely block amyloid formation by which is an indicator of cellular redox activity [5]. A
and other amyloid-forming peptides have been shown to[Lys17, Asp21]A(1-28) (data not shown).
decrease cellular redox activity. Redox activity is closelyWe next studied the effects of aged solutions of
associated with cell viability [5, 6, 8, 14, 16, 51, 56].A(1-28), cyclo17, 21-[Lys17, Asp21]A(1-28) and of a mix-
Based on this assay, the solution containing A(1-28)ture of A(1-28) with cyclo17, 21-[Lys17, Asp21]A(1-28) on
amyloid aggregates was cytotoxic to HTB14 cells (Fig-the viability of a human glioblastoma/astrocytoma cell
ure 5D). By contrast, cell viability was significantly in-line [56]. EM showed that aged A(1-28) mainly con-
creased in cells treated with cyclo17, 21-[Lys17, Asp21]sisted of amyloid aggregates (Figure 5B), whereas
A(1-28) alone and with the mixture of cyclo17, 21-[Lys17,cyclo17, 21-[Lys17, Asp21]A(1-28) and the mixture did not
Asp21]A(1-28) with A(1-28) (Figure 5D).contain amyloid (Figures 3D and 5C). Following incuba-
We next followed the aggregation of A(1-28),tion with the cells at peptide concentrations of 10 and
cyclo17, 21-[Lys17, Asp21]A(1-28), and of a mixture of both5 M, the MTT reduction assay was used to assess the
peptides using size exclusion chromatography (Figureseffect of the peptides on cell viability. This assay is
6A–6D). The main peak of A(1-28) (at 22.6 min) immedi-based on the cellular reduction of the dye 3-[4,5-dimeth-
ately after beginning the incubation corresponded toylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT),
dimeric A(1-28). NuPAGE analysis also indicated that
A(1-28) had a strong dimerization propensity (data not
shown). During the 5 days of incubation, the amount of
A(1-28) dimers rapidly decreased and an increase in
high molecular weight aggregates that were eluted in
the void volume of the column (12 min) was observed
(Figures 6E and 6F). Aggregation of A(1-28) was nearly
completed at 5 days (Figure 6D). Cyclo17, 21-[Lys17, Asp21]
A(1-28) appeared to have a similar dimerization and
aggregation propensity as A(1-28) (Figures 6A–6D). Of
note, the cyclic analog was very strongly retained on
the column, which might be due to a strong surface
exposure of the hydrophobic amyloid core sequence
18–20 due to the cyclic constraint. In the mixture of
A(1-28) with cyclo17, 21-[Lys17, Asp21]A(1-28), dimers
were also the main oligomeric forms present. The de-Figure 4. -Helical Propensities of Cyclo17, 21-[Lys17, Asp21]A(1-28),
A(1-28), and [Lys17, Asp21]A(1-28) as Assessed by Far-UV CD crease of the amount of dimers in the mixture was,
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Figure 5. Inhibitory Effect of Cyclo17, 21-[Lys17, Asp21]A(1-28) on Amyloid Formation and Cytotoxicity of A(1-28) as Assessed by Far-UV CD,
EM, and the MTT Cell Viability Assay
(A) CD spectra of a mixture of A(1-28) and cyclo17, 21-[Lys17, Asp21]A(1-28) (450 M each) at 0 hr and 8 days following the begin of incubation.
CD spectra of A(1-28) (450 M) alone at the beginning of an incubation and of cyclo17, 21-[Lys17, Asp21]A(1-28) alone (450 M) are also shown.
(B) Electron micrograph of aged A(1-28) (450 M, see [A]) at 4 days.
(C) Electron micrograph of the aged mixture of A(1-28) with cyclo17, 21-[Lys17, Asp21]A(1-28) (450 M each, see [A]) 5 days upon making the
mixture. Bars in the electron micrographs represent 100 nm.
(D) Cell viability in the presence of aged A(1-28) alone, cyclo17, 21-[Lys17, Asp21]A(1-28) alone, and a mixture of A(1-28) with cyclo17, 21-[Lys17,
Asp21]A(1-28). Data are percentages of control values (vehicle alone) and are the mean  SD of four to five determinations.
however, much slower than in A(1-28) alone (Figure 6), finally, by revealing the components of the complexes
by Western blotting against A(1-40) (by antibody) (Fig-and only very low amounts of high molecular weight
aggregates formed. This data indicated that interaction ure 7A, left panel) and by NuPAGE in combination with
an anti-streptavidin antibody to reveal the biotinylatedof cyclo17, 21-[Lys17, Asp21]A(1-28) with A(1-28) might
have resulted in formation of heterodimers that were complex component (Figure 7A, right panel). The anti-
A(1-40) Western blot showed that the retrieved amountmore resistant to further aggregation than A(1-28) di-
mers and/or that the cyclic analog might have caused of A(1-40) in the mixture with the cyclic peptide was
at least twice as high as that obtained for A(1-40) duea dissociation of high molecular weight aggregates. A
small fraction of A(1-28) in the incubation of A(1-28) to nonspecific binding to the beads (Figure 7A, left
panel). This result suggested that cyclo17, 21-[Lys17, Asp21]alone eluted as a monomer (at 27 min), and its amount
did not change during the incubation time. By contrast, A(1-28) was able to bind A(1-40).
Thioflavin T (ThT) binding to amyloid and the associ-the fraction of monomeric peptide significantly in-
creased during the incubation of the mixture (Figures ated increase in ThT fluorescence emission is used as
a specific assay for the detection of amyloid aggregates6A–6D). This indicated that interaction of the cyclic ana-
log with A(1-28) might also have resulted in a dissocia- [58]. Aged solutions of A(1-40) showed a significantly
increased ThT fluorescence emission as compared totion of dimeric or multimeric A(1-28) into monomers.
solutions containing a mixture of A(1-40) with the cyclic
analog, and no increase in ThT fluorescence was ob-Studies on the Interaction of Cyclo17, 21-[Lys17,
served in cyclo17, 21-[Lys17, Asp21]A(1-28) alone (data notAsp21]A(1-28) with A(1-40)
shown). These results indicated that the cyclic peptideTo investigate the ability of cyclo17, 21-[Lys17, Asp21]
interfered with the amyloid formation process of A(1-A(1-28) to bind A(1-40), we established an A(1-40)
40) and prompted us to undertake EM studies.pull-down assay [57] in combination with NuPAGE gel
In fact, further evidence for the interference ofelectrophoresis and Western blotting with an anti-A(1-
cyclo17, 21-[Lys17, Asp21]A(1-28) with the amyloidogen-40) antibody (Figure 7A). Complexes of the cyclic pep-
esis process of A(1-40) was obtained by EM. Agedtide and its potential interaction partner A(1-40) were
A(1-40) predominantly contained fibrils with diametersisolated via binding of the biotinylated cyclic peptide
of 6–10 nm and of indefinite lengths (Figure 7B), i.e.,on streptavidin-coated magnetic beads, the subsequent
dissociation of these complexes from the beads, and, typical values for “mature” amyloid. By contrast, solu-
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Figure 6. Interaction of Cyclo17, 21-[Lys17, Asp21]A(1-28) with A(1-28) and Inhibition of the Aggregation of A(1-28) as Followed by Size Exclusion
Chromatography at Different Time Points
A(1-28) alone, cyclo17, 21-[Lys17, Asp21]A(1-28) alone, and a mixture of A(1-28) with cyclo17, 21-[Lys17, Asp21]A(1-28) were aged for 5 days at
room temperature.
(A–D) Chromatograms at various time points including the time points 0 hr (A), 20 hr (B), 44 hr (C), and 94 hr (D) are shown. Retention times
are indicated on the chromatograms. The chromatogram of cyclo17, 21-[Lys17, Asp21]A(1-28) was subtracted from the chromatogram of the
mixture.
(E and F) Kinetics of A(1-28) aggregation alone versus in the mixture are shown. Amounts of A(1-28) dimers (E) and high molecular weight
aggregates (F) in both solutions as indicated are plotted versus time. Results shown represent results from two independent experiments.
tions of a mixture of A(1-40) with the cyclic analog Discussion
consisted of three populations of aggregates: one popu-
lation (less than 10% of the total) was similar to the Cyclo17, 21-[Lys17, Asp21]A(1-28) was unable to form 
sheets and amyloid aggregates. This could be attributedabove described fı´brils (Figure 7C), a second population
(20%–30%) consisted of short (	200 nm) fibrils (Figure to the effect of the conformational constraint as com-
pared to the substituents alone. Cyclo17, 21-[Lys17, Asp21]7D) that were strongly reminiscent of the protofibrillar
A(1-40) species that have been previously described A(1-28) was also able to self-associate into soluble,
oligo- and high molecular weight amorphous aggre-[22], and a third population consisted of amorphous
aggregates (Figure 7E) and corresponded to a major gates. These findings suggest that the conformation that
was stabilized in A(1-28) by the cyclic constraint isaggregate population.
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gates are not necessarily associated with its  sheet-
forming ability. CD studies indicated that cyclo17, 21-
[Lys17, Asp21]A(1-28) may have a higher  helix-forming
propensity than A(1-28). Thus, although NMR studies
are now necessary to determine the precise conforma-
tion of the cyclic analog, our findings are consistent with
the suggestion that an  helix to  sheet transition is
an important step in A(1-28) amyloidogenesis [18, 19,
21, 25].
According to the MTT reduction assay, aged A(1-28)
affected cellular redox activity and thus viability of a
human astroglioma/astrocytoma cell line [56, 60]. By
contrast, cyclo17, 21-[Lys17, Asp21]A(1-28) was markedly
less cytoxic. It should however be noted that, because
cellular redox ability is only one parameter of cell viability
and amyloid-mediated cell damage [5, 6, 8], additional
assays will be necessary to understand the effect of
these peptides on cells. Blocking the amyloidogenic
potential and, in some cases, also cytotoxicity of partial
A sequences by means of substituting crucial amyloid
core residues or by N-methylation of amide bonds in
the amyloid core region has previously been reported
[12, 16, 23, 28, 30]. Also, Esler et al. [59] have recently
shown that an A(10-35) congener that had a high-
energy barrier to a conformational transition did not
deposit into amyloid. The results of our work support
the above findings and show for the first time that the
direct conformational restriction of an amyloid core se-
quence via cyclization may result in inhibition of both
the amyloid-forming and the cytotoxic potential of the
native sequence.
Importantly, cyclo17, 21-[Lys17, Asp21]A(1-28) was able
to interact with A(1-28) and to inhibit its aggregation
into amyloid and its cytotoxic effect. These results are
consistent with findings that interference with and/orFigure 7. Interaction of Cyclo17, 21-[Lys17, Asp21]A(1-28) with
inhibition of A aggregation into amyloid may result inA(1-40) and the Effect on Amyloidogenesis as Assessed by a Bind-
an inhibition of amyloid-related cytotoxicity [12–14, 16].ing Assay and EM
Size exclusion chromatography indicated that interac-(A) Left panel, anti-A(1-40) Western blot analysis following pull
down of N-biotinyl-cyclo17, 21-[Aca0, Lys17, Asp21]A(1-28)/A(1-40) tion of the cyclic peptide with A(1-28) and thus the
complexes. Lane, inhibitor: N-biotinyl-cyclo17, 21-[Aca0, Lys17, Asp21] observed inhibitory effect on A(1-28) aggregation into
A(1-28) alone; lane, mixture: complex-bound A(1-40); lane, A(1- amyloid might include formation of heterodimers and/
40): A-(1-40) alone was incubated with beads (nonspecific binding); or a dissociation of A(1-28) oligomers and multimers.
lane, input (5%): 5% freshly dissolved A(1-40) (0.5 g) (not incu-
CD suggested that the above interaction was associatedbated with the beads). Nonspecific binding was thus less than 5%
with conformational changes. Association of the cyclicof total A(1-40). Arrows indicate detected monomers and dimers
of A(1-40). Right panel, identical samples were subjected to the and, potentially,  helix-stabilized A(1-28) analog with
pull-down procedure, and the blot was revealed with streptavidin- A(1-28) might have led to an assembly that may not
POD. Arrow indicates N-biotinyl-cyclo17, 21-[Aca0, Lys17, Asp21]A(1- be able to convert into amyloid fibrils due to the con-
28) oligomers. straint in the analog. In that way, A(1-28) would have
(B) Electron micrographs of aged A(1-40) (46 M) 7 days following
been sequestered from the amyloid formation pathway.incubation begin.
Such an assembly might consist of oligomeric  helices.(C–E) Electron micrographs of aggregates formed in an aged mixture
Formation of -helical oligomeric assemblies has re-of A(1-40) (46 M) with cyclo17, 21-[Lys17, Asp21]A(1-28) (60 M) at
7 days. cently been proposed to be a key on- or off-pathway
step in A(1-40) fibrillogenesis [22, 32]. A similar mecha-
nism of interaction has been proposed to account for
compatible with the high-self-association propensity of the inhibitory activity of side chain lactam-bridged and
A(1-28) but is incompatible with the potential of A(1-  helix-stabilized peptides on HIV type 1 infectivity [61].
28) to aggregate into  sheets and amyloid fibrils. These Although our studies use the nonnative fragment
findings support the suggestion that a conformational A(1-28) as a model peptide for A, it may be derived
transition into  sheets is a necessary step in A amy- from the results obtained on the interaction of cyclo17, 21-
loidogenesis [59], and additionally support the idea that [Lys17, Asp21]A(1-28) with A(1-40) that they are biologi-
the self-recognition ability of A(1-28) and its ability to cally relevant. In fact, the cyclic analog was also found
to be capable of binding A(1-40). In addition, whileself-associate into amorphous (i.e., nonamyloid) aggre-
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sized by the Boc strategy and MH 3305.3 (calculated 3304.5) forthis peptide did not inhibit aggregation of A(1-40) into
the peptide synthesized by the Fmoc strategy. [Lys17, Asp21]A(1-“mature” amyloid fibrils, it was able to interfere with
28) was synthesized using Boc-synthetic protocols and purified asthe process of amyloidogenesis. Our data indicate that
described above. MALDI-MS gave MH of 3325.1 (calculated
interference was related to formation or stabilization of 3322.5). N-terminally biotinylated cyclo17, 21-[Aca0, Lys17, Asp21]A(1-
short fibrillar A(1-40) aggregates that appeared to be 28) was synthesized by the Fmoc strategy and purified as above.

-aminocaproic acid (Aca) was used as a spacer for biotin. MALDI-similar to protofibrillar A(1-40) [22, 62]. A detailed char-
MS gave MH of 3642.3 (calculated 3644.0).acterization of the effect of the cyclic analog on amy-
loidogenesis and cytotoxicity of A(1-40) should assist
AFMin elucidation of mediators of cytotoxicity, i.e., fibrils
Peptides were incubated at 2 mM in aqueous 10% HAc for 6 days
versus protofibrils and other aggregates [9, 10, 63]. at room temperature [49]. Following neutralization with aqueous
Our study suggests that, by introducing a rationally 10% ammonium hydroxide, incubations continued for 2 months at
designed conformational constraint into an amyloid core 4C. Sample preparation and AFM with an AUTOPROBE CP Micro-
scope (Park Scientific Instruments, Sunnyvale, CA) were performedsequence and at the same time maintaining some of
as described [49]. Scanning parameters were drive amplitude be-the sequence-specific self-assembly determinants, it is
tween 5 and 6V and scan rate 1.5 Hz. Diameters of the fibrils and di-possible to convert a native amyloidogenic sequence
mensions of the aggregates were determined as described [49, 52].
into a nonamyloidogenic one which is able to interact
with the native sequence and inhibit or interfere with its Congo Red Staining
amyloidogenesis pathway and cytotoxic effects. 5 l of aged peptide solutions (2 mM peptide in 10% HAc; 6 days
incubation at room temperature; neutralization with 10% ammonium
hydroxide) were allowed to air dry on a glass microscope slide, andSignificance
staining was performed by saturated CR solution in 80% ethanol
[51]. Birefringence was determined with an OLYMPUS CK40 light
The conformational transition of A into  sheet-con- microscope (Olympus, Tokyo, Japan) under cross-polarized light.
taining amyloid is strongly associated with the patho-
genesis of AD. Here, we have applied an i, i4 side FT-IR Spectroscopy
5 l of aged peptide solutions (incubation as for AFM) were appliedchain lactam bridge conformational constraint to the
onto a CaF2 plate, air dried, and spectra measured in a Perkin-Elmeramyloid core sequence 18–20 of the amyloidogenic
spectrophotometer (Spectrum 1000) as described [51].N-terminal A sequence A(1-28). In contrast to
A(1-28), the cyclic analog cyclo17, 21-[Lys17, Asp21]A(1-
Aggregation Assays Using EM
28) is unable to aggregate into  sheets and cytotoxic Incubations of peptides were performed in assay buffer that con-
amyloid. Moreover, cyclo17, 21-[Lys17, Asp21]A(1-28) is sisted of 70% (v/v) sterile-filtered (0.22 m) 10 mM sodium phos-
phate buffer, pH 5.5, containing 100 mM NaCl and 30% (v/v) ACNshown to interact with A(1-28) and to inhibit amyloid
for several days at room temperature. At the indicated time points,formation and cytotoxicity of A(1-28). Cyclo17, 21-
5–20 l aliquots of solutions/suspensions of the aggregation assays[Lys17, Asp21]A(1-28) was also shown to be able to
were applied onto formvar/carbon-coated copper grids, stainedinteract with A(1-40) and interfere with its amyloido-
with uranyl acetate [51], and examined with a Zeiss EM 109 electron
genesis pathway. These results show for the first time microscope operated at 80kV or with a Philips EM 400 T electron
that the direct conformational restriction of the amy- microscope operated at 60kV.
loid core of an amyloidogenic sequence via cyclization
CD Spectroscopymay lead to an inhibitor of amyloidogenesis and re-
A Jasco J-720 spectropolarimeter was used. Far-UV CD spectralated cytotoxicity. Cyclo17, 21-[Lys17, Asp21]A(1-28) and
were collected between 195 or 200 and 250 nm, at 0.1 nm intervals,other accordingly modified conformationally con-
with a response time of 8 s and at room temperature. For the study
strained A analogs may be suitable candidates or of amyloidogenesis-related transitions and peptide-inhibitor inter-
lead compounds for therapeutic or diagnostic ap- actions, the assay buffer was as for EM, and peptide concentrations
proaches in AD. were 225 and 450 M. For the determination of the -helical propen-
sities, peptide concentrations of 5 M were applied, and the assay
buffer consisted of 10% TFE in 10 mM sodium phosphate buffer,Experimental Procedures
pH 3.0. These conditions have been previously shown to correspond
to very weak monomeric  helix-promoting conditions for A(1-28)Materials
Protected amino acids, resins for peptide synthesis, and coupling [19] and should allow for the detection of a potential difference
between the -helical propensities of the peptides. Of note,  helixreagents were from Bachem (Heidelberg, Germany), Rapp Polymere
(Tu¨bingen, Germany), Novabiochem (Bad Soden, Germany), and formation has been also found to not depend on the peptide concen-
tration up to the upper micromolar range [19].Advanced ChemTech (Louisville, KY). Solvents and chemicals for
syntheses, RP-HPLC purifications, and CD studies were from Merck
(Darmstadt, Germany) and Aldrich (Deisenhofen, Germany) and were Peptide Binding Studies
of the highest purity grade available. Synthetic A(1-28) and A(1-40) A(1-40) (10 g) was incubated alone or with N-biotinyl-cyclo17, 21-
were from Bachem. [Aca0, Lys17, Asp21]A(1-28) (10g) in 1 ml phosphate-buffered saline
(PBS) for 1 hr. N-biotinyl-cyclo17, 21-[Aca0, Lys17, Asp21]A(1-28) (10
g) was also incubated alone. Streptavidin-coupled magnetic beadsPeptide Synthesis, Purification, and Characterization
Cyclo17, 21-[Lys17, Asp21]A(1-28) was synthesized by Boc- and Fmoc- (Dynabeads M-280 Streptavidin, Dynal Biotec ASA, Oslo, Norway)
(100 l) were washed with PBS, a solution of 20 mM Tris, pH 7.3,solid phase synthetic protocols essentially as previously described
[43, 64, 65]. Crude cyclo17, 21-[Lys17, Asp21]A(1-28) was purified by containing 150 mM NaCl and 0.05% Tween 20 (TBSn), and blocked
with 0.25% bovine serum albumin (analysis grade) in TBSn over-RP-HPLC on a Nucleosil 100 C-18 semipreparative column (100 A˚
pore size, 7 m particle size, 8  250 mm) (Grom, Herrenberg, night. Incubations of the peptides with the beads were performed
then for 90 min and bead-bound complexes were isolated by mag-Germany) or a Vydac C-4 column (300 A˚ pore size, 100 m particle
size, 10  250 mm) as described [64]. HPLC-purified peptide was netic affinity. Beads were washed with 25 mM HEPES, pH 7.7, con-
taining 0.1 M NaCl and 0.5% Triton X100, reducing NuPAGE samplecharacterized by matrix-assisted laser desorption mass spectros-
copy (MALDI-MS) which gave MH 3306.0 for the peptide synthe- loading buffer was added, the beads were boiled (10 min), and
Inhibitor of A(1-28) Amyloidogenesis and Toxicity
157
supernatants containing the eluted complexes were subjected to work. We thank S. Stoeva and K. Laib for MALDI-MS. We thank J.
Lorenzen and H.-G. Hollweg for advice with the use of the EMNuPAGE electrophoresis in 4%–12% Bis-Tris gels with MES running
buffer according to the manufacturer’s (Invitrogen, Karlsruhe, Ger- instrument. This work was supported by a grant of The Fraunhofer
Institute for Interfacial and Biological Engineering (Stuttgart, Ger-many) recommendations. Equal amounts of peptide (3.3 g) were
loaded. Peptides were blotted onto nitrocellulose using a XCell II many) to A.K.
Blot Module blotting system (Invitrogen). A(1-40) bound to N-
biotinyl-cyclo17, 21-[Aca0, Lys17, Asp21]A(1-28) was revealed by West-
Received: June 4, 2002ern blotting using a polyclonal rabbit anti-A(1-40) antibody (Sigma,
Revised: January 6, 2003Deisenhofen, Germany) in combination with peroxidase (POD)-cou-
Accepted: January 22, 2003pled secondary antibody and the Super Signal Duration ECL staining
solution (Pierce/KMF, St. Augustin, Germany). Control blots per-
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